论文部分内容阅读
Patients with pancreatic cancer have a poor prognosiswith a median survival of 4-6 mo and a 5-year survivalof less than 5%. Despite therapy with gemcitabine,patient survival does not exceed 6 mo, likely due tonatural resistance to gemcitabine. Therefore,